ABOUT ME

-

Today
-
Yesterday
-
Total
-
  • [Korea Market] KOSPI Reclaims 7,000 Milestone on Semiconductor Export Boom
    한국증시_코스피 2026. 9. 21. 17:53

    ⚡ Market Highlights (Executive Summary)

    The KOSPI reclaimed the psychological 7,000 benchmark for the first time in 7 sessions, jumping 1.65% (+113.49 pts) to close at 7,007.72 on Monday, September 21, 2026. The rally was catalyzed by official customs trade data revealing a spectacular 259.4% YoY surge in semiconductor exports through September 20. Heavy institutional buying of KRW 1.49 trillion lifted Samsung Electronics (+4.98% to 274,000 KRW), while the tech-heavy KOSDAQ gained 1.11% to 836.27. The USD/KRW exchange rate broke its 7-day winning streak, easing to 1,381.00 KRW.

    📊 Closing Market Summary & Foreign Exchange

    Index / FX Close Change % Change
    KOSPI 7,007.72 ▲ 113.49 +1.65%
    KOSDAQ 836.27 ▲ 9.15 +1.11%
    USD/KRW 1,381.00 ▼ 2.30 -0.17%
    JPY/KRW (per 100¥) 877.62 ▼ 8.93 -1.01%

    👥 Investor Positioning (KOSPI)

    • Institutional Investors: Net buyers of +KRW 1.49 trillion, solely spearheading the afternoon breakout above 7,000.
    • Foreign Investors: Net sellers of -KRW 160.2 billion, taking a breather after morning net buying.
    • Retail Investors: Net sellers of -KRW 2.98 trillion, aggressively booking profits at the key round-number milestone.

    🔥 Top Movers & Sector Highlights

    🚀 Leaders & Gainers

    • Samsung Electronics (274,000 KRW, +4.98%): Powered ahead to reclaim the 270,000 KRW mark for the first time in 10 sessions, driven by surging chip trade volume.
    • SK Hynix (1,868,000 KRW, +0.59%): Consolidating near record highs following Friday's +6% rally, maintaining strong technical leadership.
    • Semiconductor Equipment & OSAT (Hana Micron, SFA Semi): Rallied by up to 14% intraday as optimism broadened across the domestic tech supply chain.
    • Holding Companies (SK Square +4.2%, Samsung C&T +4.1%): Lifted by rising underlying equity valuations and Corporate Value-up expectations.

    📉 Laggards & Plunging Names

    • Orum Therapeutics (27,300 KRW, -27.01%): Crashed for a second consecutive day after multinational pharma partner BMS discontinued clinical trials for licensed AML drug ORM-6151.
    • Secondary Battery Mid-Caps: Underperformed as broad-market liquidity remained heavily clustered in semiconductor bellwethers.

    ⚖️ Market Intelligence: Facts vs Rumors

    ✅ Confirmed Corporate & Macro Facts

    • Korea Customs Trade Print: Korean exports surged 78.3% YoY during September 1-20, led by an astounding 259.4% jump in semiconductor shipments, squashing memory peak-out narratives.
    • Orum Therapeutics Pipeline Halting: Formally disclosed that partner Bristol Myers Squibb (BMS) terminated the development program for ORM-6151.

    ⚠️ Market Rumors & Unconfirmed Street Chatter

    • Holiday Geopolitical Tariffs: Whispers regarding potential holiday export controls between Washington and Beijing floated around trading desks but were dismissed by strong trade metrics.
    • BOJ FX Rate Check Rumor: Speculation that Japanese monetary authorities conducted rate checks to defend the Yen triggered sharp JPY/KRW contraction toward 877 KRW.

    🌐 Macro Drivers & Next Session Watchlist

    • Consolidation Above 7,000: Establishing 7,000 as a firm structural support floor will require sustained institutional commitment against retail profit-taking.
    • USD/KRW Cooling Below 1,380: Today's retreat to 1,381.0 KRW aided by pre-holiday dollar selling provides breathing room for overseas portfolio allocators.
    • US 10-Year Yield (4.96%): Monitoring whether robust domestic export earnings can continue decoupling Korea from elevated global yields.

    ❓ Frequently Asked Questions (FAQ)

    Q. Why did KOSPI surpass 7,000 despite retail offloading nearly KRW 3 trillion?

    A. The phenomenal 259.4% surge in early September semiconductor exports completely shifted institutional sentiment, prompting aggressive accumulation of tech blue chips.

    Q. What triggered the 27% collapse in Orum Therapeutics?

    A. The discontinuation of the ORM-6151 clinical trial by licensee BMS erased near-term milestone pipeline expectations.

Designed by Tistory.